New inhaled drug hopes to clear lungs in mucus diseases

NCT ID NCT06603246

Recruiting now Symptom relief Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This early-stage study tests an inhaled drug called GDC-6988 in people with lung conditions that cause thick mucus, like non-CF bronchiectasis and COPD. The main goal is to check if the drug is safe and tolerable. About 128 adults with stable disease and good lung function will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE NON-CYSTIC FIBROSIS BRONCHIECTASIS

Contacts and locations

Locations

Accel Research Site - Achieve - Birmingham - ERN - PPDS
WITHDRAWN

Vestavia Hills, Alabama, 35216-1927, United States
Stanford Center for Excellence in Pulmonary Biology
RECRUITING

Palo Alto, California, 94304, United States
TTS Research
COMPLETED

Boerne, Texas, 78006, United States
UPMC Montefiore Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15213 3236, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35233, United States
University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd
RECRUITING

Kansas City, Kansas, 66160 8500, United States
University of North Carolina Clinical Research Center
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.